Multi-drug Resistant Organism Module
|
Active Surveillance Culturing Option
|
| | | | | | | | | ASC* Process and Outcome Measures
|
Location
| Organism
| ASC-Timing
| ASC-Eligible
| Incidence
| Prevalence
|
_____________
| _________
| Adm
| Both
| All
| NHx
|
|
|
_____________
| _________
| Adm
| Both
| All
| NHx
|
|
|
_____________
| _________
| Adm
| Both
| All
| NHx
|
|
|
_____________
| _________
| Adm
| Both
| All
| NHx
|
|
|
_____________
| _________
| Adm
| Both
| All
| NHx
|
|
|
Process and Laboratory-identified MDRO Event Monitoring Option
|
Location
| Organism
| **LIME
| HH
| GG
| | | | | |
_____________
| _________
|
|
|
| | | | | |
_____________
| _________
|
|
|
| | | | | |
_____________
| _________
|
|
|
| | | | | |
_____________
| _________
|
|
|
| | | | | |
_____________
| _________
|
|
|
| | | | | |
Patient Influenza Vaccination Module
|
Method A:
|
| | | | | | | | |
Method B:
|
| Denominator Level: (Circle One)
| Summary
| Patient Level
| | | | |
| | | | | | | | | |
|